Sorriso is a biopharmaceutical company advancing a pipeline of disease-modifying antibodies for the treatment of immune-mediated diseases, including Crohn’s disease and ulcerative colitis.

The Sorriso platform generates potent antibodies that can be delivered orally and are designed to maintain activity throughout the human intestine.

The company’s lead candidate, SOR102, is being developed for the treatment of inflammatory bowel disease (IBD). SOR102 simultaneously inhibits TNF⍺ and IL-23(p19), two clinically validated drivers of IBD.